Relmada Therapeutics Inc reports results for the quarter ended in June - Earnings Summary

Relmada Therapeutics

11/08/2022 22:02

* Relmada Therapeutics Inc  RLMD.OQ  reported a quarterly
adjusted
loss of $1.33​​ per share for the quarter ended in June. The
mean expectation of seven analysts for the quarter was for a
loss of $1.27 per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Relmada Therapeutics Inc's reported EPS for the quarter
was a
loss of $1.33​.
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Relmada Therapeutics Inc shares had risen by 54.2% this
quarter and gained 30.0% so far this year.
    * The company reported a quarterly loss of $39.93 million.
    * Wall Street's median 12-month price target for Relmada
Therapeutics Inc is $50.00 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 7 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data August 11
at 09:01 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2022      -1.27          -1.33          Missed
 Mar. 31 2022      -1.27          -1.40          Missed
 Dec. 31 2021      -1.83          -1.80          Beat
 Sep. 30 2021      -1.60          -2.44          Missed